Industry News
Proteome Systems lists, dips 15 per cent
Sydney proteomics pioneer Proteome Systems (ASX:PXL) made its long-awaited debut on the Australian Stock Exchange at noon today. [ + ]
Handle stem cells with caution: expert
Cambridge University researcher and clinician Dr Roger Barker told delegates at this week's ComBio2004 conference in Perth to exercise caution in using stem cell therapies to treat neurodegenerative diseases like Parkinson's disease. [ + ]
Blowing in the wind: gene patents
The victory of biotechnology giant Monsanto over Canadian farmer Mr Percy Schmeiser in the Supreme Court of Canada has sent a powerful message to Australian farmers - not just about GM crops, but about all plant technologies, according to ANU law expert Dr Matthew Rimmer.
[ + ]Medical researchers slam Howard's lack of support
On the eve the Federal election, some of Australia' most famous medical researchers have signed an open letter to Prime Minister John Howard and Opposition Leader Mark Latham asking them to increase funding for medical research. [ + ]
Acrux lists at a discount
Drug delivery company Acrux (ASX:ACR) listed on the ASX today at $0.90, a discount of 10 per cent to its issue price of $1.00 per share. But shares rallied slightly as the day progressed, and at time of writing were trading at $0.93. [ + ]
Late stage partnerships not always the way to go: Edwards
Recombinant Capital's Mark Edwards has some unfashionable advice for Australian life science companies: don't hold out for a late-stage partnership with a pharmaceutical company at the expense of shoring up the company's future with early stage deals. [ + ]
BioDioem eyes vision drug market
Melbourne biopharma BioDiem (ASX:BDM) has entered the race to develop a treatment for the ophthalmic disorder, age-related macular degeneration (AMD), by taking a licence for a Russian-developed peptide therapeutic that has shown high promise in an Australian clinical trial. [ + ]
Healthy ASX listing for Sunshine Heart
Sunshine Heart (ASX: SHC) listed on the ASX today at AUD$0.60 -- 10 cents above its issue price. But at time of writing the cardiac company's shares had slipped slightly lower to AUD$0.57. [ + ]
Pharmas desperately need academic guidance: Cohen
The University of Dundee's Sir Philip Cohen believes that pharmaceutical companies desperately need the help of academic labs, as drug development requires more and more knowledge about biological mechanisms to specifically target drugs. [ + ]
Pharmaxis breathing easier after positive Phase II results
Pharmaxis (ASX:PXS) investors will be breathing easy after the company announced a positive result from its Phase II clinical trial of Bronchitol, its lead compound for treating the chronic lung disorder bronchiectasis. [ + ]
Boston's Athena Diagnostics to market Bionomics epilepsy test
South Australian biopharma Bionomics(ASX:BNO) announced today it has licensed Boston company Athena Diagnostics to market its test for severe myoclonic epilepsy of infancy (SMEI) to neurologists in North America and Japan. [ + ]
Iliad hits homer with first drug
Unlisted Melbourne drug-development company Iliad Chemicals has reported promising results from a pre-clinical trial of its first anti-cancer drug, developed with its proprietary Multicore drug-synthesis technology. [ + ]
Combio 2004 - be altruistic, scientists told
Eminent burns surgeon Fiona Wood has opened the ComBio 2004 meeting in Perth with an appeal to scientists' altruism. [ + ]
Genetic basis for metabolic diseases detected
Oxford geneticists have closed in on the genetic basis for risk factors of metabolic diseases such as hypertension, obesity and diabetes.
[ + ]Peptech ready for growth
Peptech (ASX: PTD) is keenly awaiting the day the Centocor decision is handed down by the arbitrators. [ + ]
